| pubmed-article:9661010 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9661010 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9661010 | lifeskim:mentions | umls-concept:C0019004 | lld:lifeskim |
| pubmed-article:9661010 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:9661010 | lifeskim:mentions | umls-concept:C0007732 | lld:lifeskim |
| pubmed-article:9661010 | lifeskim:mentions | umls-concept:C0060405 | lld:lifeskim |
| pubmed-article:9661010 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:9661010 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:9661010 | pubmed:dateCreated | 1998-10-8 | lld:pubmed |
| pubmed-article:9661010 | pubmed:abstractText | The pharmacokinetics of cefdinir were investigated in six hemodialysis patients. For the present study, two tests were carried out, one with 4 h of hemodialysis and the other without hemodialysis. Cefdinir was given orally to each patient in a dose of 100 mg, and blood was collected serially for 48 h after dosing in the test without dialysis and for 72 h in the test with dialysis. In the test without dialysis, the maximum plasma concentration (Cmax) was 2.36 +/- 0.53 micrograms/ml (mean +/- standard deviation) and the time to Cmax was 9.00 +/- 2.45 h. The terminal elimination half-life (t1/2) and area under the concentration-time curve (AUC) were 16.95 +/- 1.20 h and 69.05 +/- 14.84 micrograms.h/ml, respectively. In the test with dialysis, t1/2 during hemodialysis decreased approximately to one-sixth of that obtained in the test without dialysis, although t1/2 in the latter elimination phase did not differ from that in the nondialysis test. AUC was reduced to 43% of that in the test without dialysis. The fractional removal of cefdinir by hemodialysis was 61%. These findings indicate that clearance of cefdinir is prolonged in patients with renal failure, and cefdinir is well removed by introduction of hemodialysis, although t1/2 (during hemodialysis) and AUC were two and eight times higher than the data previously reported for healthy volunteers, respectively. The pharmacokinetic data suggest that 100 mg of oral cefdinir once a day would result in a sufficient concentration in plasma in hemodialysis patients, but this remains to be confirmed by multiple-dose studies. | lld:pubmed |
| pubmed-article:9661010 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9661010 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9661010 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9661010 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9661010 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9661010 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9661010 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9661010 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9661010 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9661010 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9661010 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9661010 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9661010 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9661010 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9661010 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9661010 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:9661010 | pubmed:issn | 0066-4804 | lld:pubmed |
| pubmed-article:9661010 | pubmed:author | pubmed-author:ObaraMM | lld:pubmed |
| pubmed-article:9661010 | pubmed:author | pubmed-author:NagashimaSS | lld:pubmed |
| pubmed-article:9661010 | pubmed:author | pubmed-author:OhishiKK | lld:pubmed |
| pubmed-article:9661010 | pubmed:author | pubmed-author:KanamaruMM | lld:pubmed |
| pubmed-article:9661010 | pubmed:author | pubmed-author:HishidaAA | lld:pubmed |
| pubmed-article:9661010 | pubmed:author | pubmed-author:KitadaAA | lld:pubmed |
| pubmed-article:9661010 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9661010 | pubmed:volume | 42 | lld:pubmed |
| pubmed-article:9661010 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9661010 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9661010 | pubmed:pagination | 1718-21 | lld:pubmed |
| pubmed-article:9661010 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:9661010 | pubmed:meshHeading | pubmed-meshheading:9661010-... | lld:pubmed |
| pubmed-article:9661010 | pubmed:meshHeading | pubmed-meshheading:9661010-... | lld:pubmed |
| pubmed-article:9661010 | pubmed:meshHeading | pubmed-meshheading:9661010-... | lld:pubmed |
| pubmed-article:9661010 | pubmed:meshHeading | pubmed-meshheading:9661010-... | lld:pubmed |
| pubmed-article:9661010 | pubmed:meshHeading | pubmed-meshheading:9661010-... | lld:pubmed |
| pubmed-article:9661010 | pubmed:meshHeading | pubmed-meshheading:9661010-... | lld:pubmed |
| pubmed-article:9661010 | pubmed:meshHeading | pubmed-meshheading:9661010-... | lld:pubmed |
| pubmed-article:9661010 | pubmed:meshHeading | pubmed-meshheading:9661010-... | lld:pubmed |
| pubmed-article:9661010 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9661010 | pubmed:articleTitle | Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients. | lld:pubmed |
| pubmed-article:9661010 | pubmed:affiliation | First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. ahishida@hama-med.ac.jp | lld:pubmed |
| pubmed-article:9661010 | pubmed:publicationType | Journal Article | lld:pubmed |
